EXAGEN INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Exagen Inc. on August 5, 2021, with the earliest event reported on that date. The filing primarily addresses the termination of a material definitive agreement and references the company's financial results for the three and six months ended June 30, 2021, which were reported on August 9, 2021.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is not included in the provided text. The only specific financial figure disclosed in this document is a $0.6 million consideration payment related to the termination of an agreement.
Material Changes
- Termination of Co-Promotion Agreement: On August 5, 2021, Exagen Inc. and Janssen Biotech, Inc. mutually agreed to terminate their Co-Promotion Agreement, originally dated December 10, 2018. The termination is effective August 31, 2021.
- Financial Consideration: In connection with the termination, the Company is entitled to receive an aggregate of $0.6 million.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, or a detailed discussion of risks within the main text. It notes that the financial results for the period ended June 30, 2021, are furnished via a press release (Exhibit 99.1) and explicitly states that this information is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full financial results for the three and six months ended June 30, 2021, by reviewing the press release in Exhibit 99.1.
- Confirm the impact of the terminated Co-Promotion Agreement on future revenue streams and operational costs.
- Assess the timing and certainty of receiving the $0.6 million termination consideration.
- Review the company's liquidity position given the loss of the co-promotion partnership.